|
Market Closed -
Sao Paulo
21:59:13 05/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 184.49 BRL | -2.02% |
|
-2.01% | +14.59% |
| 10-02 | Biogen's experimental lupus drug shows benefit against skin symptoms | RE |
| 10-02 | Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data | MT |
| Market Cap | 33.04B 165B 29.47B 27.46B 24.99B 47.06B 3,182B 47.4B 332B 129B 1,624B 124B 121B 5,220B | P/E 2026 * |
36.5x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 37.97B 189B 33.88B 31.56B 28.72B 54.09B 3,657B 54.49B 381B 148B 1,867B 143B 139B 6,000B | EV / Sales 2026 * |
3.64x | EV / Sales 2027 * | 3.33x |
| Free-Float |
85.8% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biogen Inc.
| 1 day | -2.02% | ||
| 1 week | -2.01% | ||
| Current month | -2.01% | ||
| 1 month | -2.02% | ||
| 3 months | +0.21% | ||
| 6 months | +15.19% | ||
| Current year | +14.59% |
| 1 week | 184.49 |  | 185.82 |
| 1 month | 184.49 | | 188.28 |
| Current year | 147.5 | | 191 |
| 1 year | 128.69 | | 191 |
| 3 years | 110.07 | | 225 |
| 5 years | 110.07 | | 277 |
| 10 years | 110.07 | | 360 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 14/11/2022 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 01/03/2025 |
Daniel Quirk
CTO | Chief Tech/Sci/R&D Officer | - | 28/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 69 | 23/03/2010 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 01/01/2010 |
William Hawkins
BRD | Director/Board Member | 72 | 19/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.02% | -2.01% | - | - | 32.49B | |
| +0.02% | -3.52% | +36.11% | +111.11% | 1,019B | |
| -1.21% | -6.99% | +34.08% | +60.96% | 617B | |
| +1.12% | -0.20% | +13.62% | +80.24% | 464B | |
| -3.30% | -6.15% | +56.45% | +34.69% | 356B | |
| +0.93% | -1.83% | +21.65% | +41.43% | 333B | |
| +0.12% | -4.05% | +10.70% | +33.53% | 267B | |
| -0.89% | -5.83% | -7.00% | +7.91% | 244B | |
| -0.01% | -3.62% | +35.28% | +52.02% | 218B | |
| -0.08% | -4.98% | +28.34% | +93.61% | 179B | |
| Average | -0.01% | -3.74% | +25.47% | +57.28% | 410.8B | |
| Weighted average by Cap. | +0.42% | -3.63% | +28.50% | +68.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.44B 52.1B 9.32B 8.68B 7.9B 14.88B 1,006B 14.99B 105B 40.81B 513B 39.21B 38.36B 1,650B | 10.66B 53.17B 9.51B 8.86B 8.06B 15.18B 1,026B 15.29B 107B 41.64B 524B 40.01B 39.15B 1,684B |
| Net income | 997M 4.97B 889M 828M 754M 1.42B 96B 1.43B 10.01B 3.89B 49B 3.74B 3.66B 157B | 1.86B 9.27B 1.66B 1.54B 1.41B 2.65B 179B 2.67B 18.67B 7.26B 91.37B 6.98B 6.83B 294B |
| Net Debt | 4.94B 24.63B 4.4B 4.1B 3.73B 7.03B 475B 7.08B 49.58B 19.29B 243B 18.53B 18.13B 780B | 2.42B 12.07B 2.16B 2.01B 1.83B 3.45B 233B 3.47B 24.3B 9.46B 119B 9.08B 8.89B 382B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIIB Stock
- BIIB34 Stock
Select your edition
All financial news and data tailored to specific country editions
